{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:01:19Z","timestamp":1788984079546,"version":"build-2803163510"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40120-021-00282-z","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T19:02:43Z","timestamp":1631818963000},"page":"609-626","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Development of Pharmacological Therapies for Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"10","author":[{"given":"Ping","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Cordato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3695-4386","authenticated-orcid":false,"given":"Jianqun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"282_CR1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bbadis.2004.08.014","volume":"1739","author":"LI Binder","year":"2005","unstructured":"Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, et al. Tau, tangles, and Alzheimer\u2019s disease. Biochim Biophys Acta. 2005;1739:216\u201323.","journal-title":"Biochim Biophys Acta"},{"key":"282_CR2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2018.02.001","volume":"14","author":"A As","year":"2018","unstructured":"As A. 2018 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2018;14:367\u2013425.","journal-title":"Alzheimers Dement"},{"key":"282_CR3","volume":"6","author":"J Cummings","year":"2020","unstructured":"Cummings J, Lee G, Ritter A, et al. Alzheimer\u2019s disease drug development pipeline: 2020. Alzheimers Dement (N Y). 2020;6: e12050.","journal-title":"Alzheimers Dement (N Y)."},{"key":"282_CR4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3233\/JAD-2010-1221","volume":"19","author":"MP Murphy","year":"2010","unstructured":"Murphy MP, LeVine H 3rd. Alzheimer\u2019s disease and the amyloid-beta peptide. J Alzheimers Dis. 2010;19:311\u201323.","journal-title":"J Alzheimers Dis"},{"key":"282_CR5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61:46\u201354.","journal-title":"Neurology"},{"key":"282_CR6","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm840","volume":"9","author":"JA Nicoll","year":"2003","unstructured":"Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9:448\u201352.","journal-title":"Nat Med"},{"key":"282_CR7","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3233\/JAD-150376","volume":"51","author":"F Pasquier","year":"2016","unstructured":"Pasquier F, Sadowsky C, Holstein A, et al. Two phase 2 multiple ascending-dose studies of vanutide cridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate Alzheimer\u2019s disease. J Alzheimers Dis. 2016;51:1131\u201343.","journal-title":"J Alzheimers Dis"},{"key":"282_CR8","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2174\/1567205014666170117101537","volume":"14","author":"M Hull","year":"2017","unstructured":"Hull M, Sadowsky C, Arai H, et al. Long-term extensions of randomized vaccination trials of ACC-001 and QS-21 in mild to moderate Alzheimer\u2019s disease. Curr Alzheimer Res. 2017;14:696\u2013708.","journal-title":"Curr Alzheimer Res"},{"key":"282_CR9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.10253","volume":"52","author":"R Dodel","year":"2002","unstructured":"Dodel R, Hampel H, Depboylu C, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer\u2019s disease. Ann Neurol. 2002;52:253\u20136.","journal-title":"Ann Neurol"},{"key":"282_CR10","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1212\/WNL.0000000000003904","volume":"88","author":"NR Relkin","year":"2017","unstructured":"Relkin NR, Thomas RG, Rissman RA, et al. A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. 2017;88:1768\u201375.","journal-title":"Neurology"},{"key":"282_CR11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/jnnp-2015-311486","volume":"88","author":"S Kile","year":"2017","unstructured":"Kile S, Au W, Parise C, et al. IVIG treatment of mild cognitive impairment due to Alzheimer\u2019s disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia. J Neurol Neurosurg Psychiatry. 2017;88:106\u201312.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"282_CR12","volume":"12","author":"T Kasai","year":"2017","unstructured":"Kasai T, Kondo M, Ishii R, et al. Abeta levels in the jugular vein and high molecular weight Abeta oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer\u2019s disease. PLoS ONE. 2017;12: e0174630.","journal-title":"PLoS ONE"},{"key":"282_CR13","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/srep01302","volume":"3","author":"LA Miles","year":"2013","unstructured":"Miles LA, Crespi GA, Doughty L, et al. Bapineuzumab captures the N-terminus of the Alzheimer\u2019s disease amyloid-beta peptide in a helical conformation. Sci Rep. 2013;3:1302.","journal-title":"Sci Rep"},{"key":"282_CR14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","volume":"8","author":"R Vandenberghe","year":"2016","unstructured":"Vandenberghe R, Rinne JO, Boada M, et al. Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016;8:18.","journal-title":"Alzheimers Res Ther"},{"key":"282_CR15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1212\/WNL.0000000000001877","volume":"85","author":"E Liu","year":"2015","unstructured":"Liu E, Schmidt ME, Margolin R, et al. Amyloid-beta 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology. 2015;85:692\u2013700.","journal-title":"Neurology"},{"key":"282_CR16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3233\/JAD-151065","volume":"53","author":"A Russu","year":"2016","unstructured":"Russu A, Samtani MN, Xu S, et al. Biomarker exposure-response analysis in mild-to-moderate Alzheimer\u2019s disease trials of bapineuzumab. J Alzheimers Dis. 2016;53:535\u201346.","journal-title":"J Alzheimers Dis"},{"key":"282_CR17","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3233\/JAD-150448","volume":"49","author":"G Novak","year":"2016","unstructured":"Novak G, Fox N, Clegg S, et al. Changes in brain volume with bapineuzumab in mild to moderate Alzheimer\u2019s disease. J Alzheimers Dis. 2016;49:1123\u201334.","journal-title":"J Alzheimers Dis"},{"key":"282_CR18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13195-016-0193-y","volume":"8","author":"A Ivanoiu","year":"2016","unstructured":"Ivanoiu A, Pariente J, Booth K, et al. Long-term safety and tolerability of bapineuzumab in patients with Alzheimer\u2019s disease in two phase 3 extension studies. Alzheimers Res Ther. 2016;8:24.","journal-title":"Alzheimers Res Ther"},{"key":"282_CR19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3233\/JAD-160216","volume":"57","author":"N Ketter","year":"2017","unstructured":"Ketter N, Brashear HR, Bogert J, et al. Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease patients. J Alzheimers Dis. 2017;57:557\u201373.","journal-title":"J Alzheimers Dis"},{"key":"282_CR20","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3233\/JAD-160369","volume":"54","author":"M Brody","year":"2016","unstructured":"Brody M, Liu E, Di J, et al. A phase II, randomized, double-blind, placebo-controlled study of safety, pharmacokinetics, and biomarker results of subcutaneous bapineuzumab in patients with mild to moderate Alzheimer\u2019s disease. J Alzheimers Dis. 2016;54:1509\u201319.","journal-title":"J Alzheimers Dis"},{"key":"282_CR21","doi-asserted-by":"crossref","first-page":"18325","DOI":"10.1074\/jbc.M117.801514","volume":"292","author":"J Zhao","year":"2017","unstructured":"Zhao J, Nussinov R, Ma B. Mechanisms of recognition of amyloid-beta (Abeta) monomer, oligomer, and fibril by homologous antibodies. J Biol Chem. 2017;292:18325\u201343.","journal-title":"J Biol Chem"},{"key":"282_CR22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:311\u201321.","journal-title":"N Engl J Med"},{"key":"282_CR23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jalz.2015.06.1893","volume":"12","author":"ER Siemers","year":"2016","unstructured":"Siemers ER, Sundell KL, Carlson C, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer\u2019s disease patients. Alzheimers Dement. 2016;12:110\u201320.","journal-title":"Alzheimers Dement"},{"key":"282_CR24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease. N Engl J Med. 2018;378:321\u201330.","journal-title":"N Engl J Med"},{"key":"282_CR25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","volume":"10","author":"S Salloway","year":"2018","unstructured":"Salloway S, Honigberg LA, Cho W, et al. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer\u2019s disease (BLAZE). Alzheimers Res Ther. 2018;10:96.","journal-title":"Alzheimers Res Ther"},{"key":"282_CR26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ana.25513","volume":"86","author":"T Yang","year":"2019","unstructured":"Yang T, Dang Y, Ostaszewski B, et al. Target engagement in an alzheimer trial: crenezumab lowers amyloid beta oligomers in cerebrospinal fluid. Ann Neurol. 2019;86:215\u201324.","journal-title":"Ann Neurol"},{"key":"282_CR27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature. 2016;537:50\u20136.","journal-title":"Nature"},{"key":"282_CR28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13195-016-0177-y","volume":"8","author":"M Delnomdedieu","year":"2016","unstructured":"Delnomdedieu M, Duvvuri S, Li DJ, et al. First-in-human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer\u2019s disease. Alzheimers Res Ther. 2016;8:12.","journal-title":"Alzheimers Res Ther"},{"key":"282_CR29","volume":"10","author":"N Andreasen","year":"2015","unstructured":"Andreasen N, Simeoni M, Ostlund H, et al. First administration of the Fc-attenuated anti-beta amyloid antibody GSK933776 to patients with mild Alzheimer\u2019s disease: a randomized, placebo-controlled study. PLoS ONE. 2015;10: e0098153.","journal-title":"PLoS ONE"},{"key":"282_CR30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","volume":"8","author":"V Logovinsky","year":"2016","unstructured":"Logovinsky V, Satlin A, Lai R, et al. Safety and tolerability of BAN2401\u2014a clinical study in Alzheimer\u2019s disease with a protofibril selective Abeta antibody. Alzheimers Res Ther. 2016;8:14.","journal-title":"Alzheimers Res Ther"},{"key":"282_CR31","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer's disease. N Engl J Med. 2021;384:1691\u2013704.","journal-title":"N Engl J Med"},{"key":"282_CR32","first-page":"691","volume":"47","author":"A Nordberg","year":"2015","unstructured":"Nordberg A, Kadir A, Andreasen N, et al. Correlations between Alzheimer\u2019s disease cerebrospinal fluid biomarkers and cerebral glucose metabolism after 12 months of phenserine treatment. J Alzheimers Dis. 2015;47:691\u2013704.","journal-title":"J Alzheimers Dis"},{"key":"282_CR33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1567205014666170117141330","volume":"14","author":"B Decourt","year":"2017","unstructured":"Decourt B, Drumm-Gurnee D, Wilson J, et al. Poor safety and tolerability hamper reaching a potentially therapeutic dose in the use of thalidomide for Alzheimer\u2019s disease: results from a double-blind, placebo-controlled trial. Curr Alzheimer Res. 2017;14:403\u201311.","journal-title":"Curr Alzheimer Res"},{"key":"282_CR34","doi-asserted-by":"crossref","first-page":"30797","DOI":"10.1074\/jbc.M505249200","volume":"280","author":"D Dominguez","year":"2005","unstructured":"Dominguez D, Tournoy J, Hartmann D, et al. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem. 2005;280:30797\u2013806.","journal-title":"J Biol Chem"},{"key":"282_CR35","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3233\/JAD-160701","volume":"55","author":"G Cebers","year":"2017","unstructured":"Cebers G, Alexander RC, Haeberlein SB, et al. AZD3293: pharmacokinetic and pharmacodynamic effects in healthy subjects and patients with Alzheimer\u2019s disease. J Alzheimers Dis. 2017;55:1039\u201353.","journal-title":"J Alzheimers Dis"},{"key":"282_CR36","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad9704","volume":"8","author":"ME Kennedy","year":"2016","unstructured":"Kennedy ME, Stamford AW, Chen X, et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in Alzheimer\u2019s disease patients. Sci Transl Med. 2016;8: 363ra150.","journal-title":"Sci Transl Med."},{"key":"282_CR37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13195-018-0415-6","volume":"10","author":"M Timmers","year":"2018","unstructured":"Timmers M, Streffer JR, Russu A, et al. Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer\u2019s disease: randomized, double-blind, placebo-controlled study. Alzheimers Res Ther. 2018;10:85.","journal-title":"Alzheimers Res Ther"},{"key":"282_CR38","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809316","volume":"10","author":"U Neumann","year":"2018","unstructured":"Neumann U, Ufer M, Jacobson LH, et al. The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer\u2019s disease. EMBO Mol Med. 2018;10: e9316.","journal-title":"EMBO Mol Med"},{"key":"282_CR39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1474-4422(13)70276-X","volume":"13","author":"R Yan","year":"2014","unstructured":"Yan R, Vassar R. Targeting the beta secretase BACE1 for Alzheimer\u2019s disease therapy. Lancet Neurol. 2014;13:319\u201329.","journal-title":"Lancet Neurol"},{"key":"282_CR40","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1111\/bph.14582","volume":"176","author":"U Neumann","year":"2019","unstructured":"Neumann U, Machauer R, Shimshek DR. The beta-secretase (BACE) inhibitor NB-360 in preclinical models: from amyloid-beta reduction to downstream disease-relevant effects. Br J Pharmacol. 2019;176:3435\u201346.","journal-title":"Br J Pharmacol"},{"key":"282_CR41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13024-015-0033-8","volume":"10","author":"U Neumann","year":"2015","unstructured":"Neumann U, Rueeger H, Machauer R, et al. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-beta and neuroinflammation in APP transgenic mice. Mol Neurodegener. 2015;10:44.","journal-title":"Mol Neurodegener"},{"key":"282_CR42","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1124\/jpet.116.232256","volume":"358","author":"HD Soares","year":"2016","unstructured":"Soares HD, Gasior M, Toyn JH, et al. The gamma-secretase modulator, BMS-932481, modulates abeta peptides in the plasma and cerebrospinal fluid of healthy volunteers. J Pharmacol Exp Ther. 2016;358:138\u201350.","journal-title":"J Pharmacol Exp Ther"},{"key":"282_CR43","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","volume":"72","author":"V Coric","year":"2015","unstructured":"Coric V, Salloway S, van Dyck CH, et al. Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial. JAMA Neurol. 2015;72:1324\u201333.","journal-title":"JAMA Neurol"},{"key":"282_CR44","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"CC Liu","year":"2013","unstructured":"Liu CC, Liu CC, Kanekiyo T, et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106\u201318.","journal-title":"Nat Rev Neurol"},{"key":"282_CR45","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1074\/jbc.M113.526095","volume":"289","author":"J Zhao","year":"2014","unstructured":"Zhao J, Fu Y, Liu CC, et al. Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor\/retinoic acid receptor pathway. J Biol Chem. 2014;289:11282\u201392.","journal-title":"J Biol Chem"},{"key":"282_CR46","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13195-016-0173-2","volume":"8","author":"JL Cummings","year":"2016","unstructured":"Cummings JL, Zhong K, Kinney JW, et al. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer\u2019s disease. Alzheimers Res Ther. 2016;8:4.","journal-title":"Alzheimers Res Ther"},{"key":"282_CR47","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","volume":"98","author":"RB DeMattos","year":"2001","unstructured":"DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci USA. 2001;98:8850\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"282_CR48","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3233\/JAD-160565","volume":"56","author":"M Boada","year":"2017","unstructured":"Boada M, Anaya F, Ortiz P, et al. Efficacy and safety of plasma exchange with 5% albumin to modify cerebrospinal fluid and plasma amyloid-beta concentrations and cognition outcomes in Alzheimer\u2019s disease patients: a multicenter, randomized controlled clinical trial. J Alzheimers Dis. 2017;56:129\u201343.","journal-title":"J Alzheimers Dis"},{"key":"282_CR49","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/aps.2017.28","volume":"38","author":"GF Chen","year":"2017","unstructured":"Chen GF, Xu TH, Yan Y, et al. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin. 2017;38:1205\u201335.","journal-title":"Acta Pharmacol Sin"},{"key":"282_CR50","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1474-4422(16)30331-3","volume":"16","author":"P Novak","year":"2017","unstructured":"Novak P, Schmidt R, Kontsekova E, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 2017;16:123\u201334.","journal-title":"Lancet Neurol"},{"key":"282_CR51","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","volume":"388","author":"S Gauthier","year":"2016","unstructured":"Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016;388:2873\u201384.","journal-title":"Lancet"},{"key":"282_CR52","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3233\/JAD-160544","volume":"54","author":"CB Malpas","year":"2016","unstructured":"Malpas CB, Vivash L, Genc S, et al. A phase IIa randomized control trial of VEL015 (Sodium Selenate) in mild-moderate Alzheimer\u2019s disease. J Alzheimers Dis. 2016;54:223\u201332.","journal-title":"J Alzheimers Dis"},{"key":"282_CR53","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3233\/JAD-142874","volume":"44","author":"CM Wischik","year":"2015","unstructured":"Wischik CM, Staff RT, Wischik DJ, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer\u2019s disease. J Alzheimers Dis. 2015;44:705\u201320.","journal-title":"J Alzheimers Dis"},{"key":"282_CR54","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nm.1912","volume":"15","author":"AH Nagahara","year":"2009","unstructured":"Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer\u2019s disease. Nat Med. 2009;15:331\u20137.","journal-title":"Nat Med"},{"key":"282_CR55","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1523\/JNEUROSCI.15-09-06213.1995","volume":"15","author":"SA Scott","year":"1995","unstructured":"Scott SA, Mufson EJ, Weingartner JA, et al. Nerve growth factor in Alzheimer\u2019s disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci. 1995;15:6213\u201321.","journal-title":"J Neurosci"},{"key":"282_CR56","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3233\/JAD-141068","volume":"43","author":"D Ferreira","year":"2015","unstructured":"Ferreira D, Westman E, Eyjolfsdottir H, et al. Brain changes in Alzheimer\u2019s disease patients with implanted encapsulated cells releasing nerve growth factor. J Alzheimers Dis. 2015;43:1059\u201372.","journal-title":"J Alzheimers Dis"},{"key":"282_CR57","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/jamaneurol.2015.1807","volume":"72","author":"MH Tuszynski","year":"2015","unstructured":"Tuszynski MH, Yang JH, Barba D, et al. Nerve growth factor gene therapy: activation of neuronal responses in Alzheimer disease. JAMA Neurol. 2015;72:1139\u201347.","journal-title":"JAMA Neurol"},{"key":"282_CR58","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13195-016-0195-9","volume":"8","author":"H Eyjolfsdottir","year":"2016","unstructured":"Eyjolfsdottir H, Eriksdotter M, Linderoth B, et al. Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer\u2019s disease patients: application of a second-generation encapsulated cell biodelivery device. Alzheimers Res Ther. 2016;8:30.","journal-title":"Alzheimers Res Ther"},{"key":"282_CR59","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","volume":"66","author":"PT Francis","year":"1999","unstructured":"Francis PT, Palmer AM, Snape M, et al. The cholinergic hypothesis of Alzheimer\u2019s disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66:137\u201347.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"282_CR60","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1468-1331.2000.00046.x","volume":"7","author":"V Kumar","year":"2000","unstructured":"Kumar V, Anand R, Messina J, et al. An efficacy and safety analysis of Exelon in Alzheimer\u2019s disease patients with concurrent vascular risk factors. Eur J Neurol. 2000;7:159\u201369.","journal-title":"Eur J Neurol"},{"key":"282_CR61","volume":"12","author":"KW Park","year":"2017","unstructured":"Park KW, Kim EJ, Han HJ, et al. Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer\u2019s dementia associated with minimal and moderate ischemic white matter hyperintensities: a multicenter prospective open-label clinical trial. PLoS ONE. 2017;12: e0182123.","journal-title":"PLoS ONE"},{"key":"282_CR62","first-page":"245","volume":"2","author":"A Wentrup","year":"2009","unstructured":"Wentrup A, Oertel WH, Dodel R. Once-daily transdermal rivastigmine in the treatment of Alzheimer\u2019s disease. Drug Des Dev Ther. 2009;2:245\u201354.","journal-title":"Drug Des Dev Ther"},{"key":"282_CR63","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/cns.12385","volume":"21","author":"MR Farlow","year":"2015","unstructured":"Farlow MR, Sadowsky CH, Velting DM, et al. Evaluating response to high-dose 13.3 mg\/24 h rivastigmine patch in patients with severe Alzheimer\u2019s disease. CNS Neurosci Ther. 2015;21:513\u20139.","journal-title":"CNS Neurosci Ther"},{"key":"282_CR64","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/1533317515603687","volume":"31","author":"RS Isaacson","year":"2016","unstructured":"Isaacson RS, Ferris S, Velting DM, et al. Cognitive efficacy (SIB) of 13.3 versus 4.6 mg\/24 h rivastigmine patch in severe Alzheimer\u2019s disease. Am J Alzheimers Dis Other Dement. 2016;31:270\u20137.","journal-title":"Am J Alzheimers Dis Other Dement"},{"key":"282_CR65","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/1567205011666141218122835","volume":"12","author":"GT Grossberg","year":"2015","unstructured":"Grossberg GT, Farlow MR, Meng X, et al. Evaluating high-dose rivastigmine patch in severe Alzheimer\u2019s disease: analyses with concomitant memantine usage as a factor. Curr Alzheimer Res. 2015;12:53\u201360.","journal-title":"Curr Alzheimer Res"},{"key":"282_CR66","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/gps.4247","volume":"30","author":"G D'Onofrio","year":"2015","unstructured":"D\u2019Onofrio G, Sancarlo D, Addante F, et al. A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2015;30:965\u201375.","journal-title":"Int J Geriatr Psychiatry"},{"key":"282_CR67","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000366198","volume":"73","author":"HJ Han","year":"2015","unstructured":"Han HJ, Kwon JC, Kim JE, et al. Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer\u2019s disease. Eur Neurol. 2015;73:23\u20138.","journal-title":"Eur Neurol"},{"key":"282_CR68","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/jnnp.2004.038729","volume":"76","author":"NI Bohnen","year":"2005","unstructured":"Bohnen NI, Kaufer DI, Hendrickson R, et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2005;76:315\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"282_CR69","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/ane.12571","volume":"135","author":"SH Han","year":"2017","unstructured":"Han SH, Lee JH, Kim SY, et al. Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer\u2019s disease. Acta Neurol Scand. 2017;135:252\u20136.","journal-title":"Acta Neurol Scand"},{"key":"282_CR70","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3233\/JAD-151149","volume":"52","author":"A Homma","year":"2016","unstructured":"Homma A, Atarashi H, Kubota N, et al. Efficacy and safety of sustained release donepezil high dose versus immediate release donepezil standard dose in Japanese patients with severe Alzheimer\u2019s disease: a randomized double-blind trial. J Alzheimers Dis. 2016;52:345\u201357.","journal-title":"J Alzheimers Dis"},{"key":"282_CR71","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s13311-016-0511-x","volume":"14","author":"TN Chase","year":"2017","unstructured":"Chase TN, Farlow MR, Clarence-Smith K. Donepezil plus solifenacin (CPC-201) treatment for Alzheimer\u2019s disease. Neurotherapeutics. 2017;14:405\u201316.","journal-title":"Neurotherapeutics"},{"key":"282_CR72","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S1474-4422(15)00258-6","volume":"14","author":"R Howard","year":"2015","unstructured":"Howard R, McShane R, Lindesay J, et al. Nursing home placement in the donepezil and memantine in moderate to severe Alzheimer\u2019s disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurol. 2015;14:1171\u201381.","journal-title":"Lancet Neurol"},{"key":"282_CR73","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jamda.2015.08.019","volume":"17","author":"N Herrmann","year":"2016","unstructured":"Herrmann N, O\u2019Regan J, Ruthirakuhan M, et al. A randomized placebo-controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease. J Am Med Dir Assoc. 2016;17:142\u20137.","journal-title":"J Am Med Dir Assoc"},{"key":"282_CR74","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jalz.2014.10.003","volume":"11","author":"B Dubois","year":"2015","unstructured":"Dubois B, Chupin M, Hampel H, et al. Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer\u2019s disease. Alzheimers Dement. 2015;11:1041\u20139.","journal-title":"Alzheimers Dement"},{"key":"282_CR75","doi-asserted-by":"crossref","first-page":"e1631","DOI":"10.4088\/JCP.15m10413","volume":"77","author":"E Cavedo","year":"2016","unstructured":"Cavedo E, Dubois B, Colliot O, et al. Reduced regional cortical thickness rate of change in donepezil-treated subjects with suspected prodromal Alzheimer\u2019s disease. J Clin Psychiatry. 2016;77:e1631\u20138.","journal-title":"J Clin Psychiatry"},{"key":"282_CR76","first-page":"391","volume":"10","author":"K Hager","year":"2014","unstructured":"Hager K, Baseman AS, Nye JS, et al. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer\u2019s disease. Neuropsychiatr Dis Treat. 2014;10:391\u2013401.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"282_CR77","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13195-016-0214-x","volume":"8","author":"K Hager","year":"2016","unstructured":"Hager K, Baseman AS, Nye JS, et al. Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer\u2019s disease: post-hoc analysis of a randomized placebo-controlled study. Alzheimers Res Ther. 2016;8:47.","journal-title":"Alzheimers Res Ther"},{"key":"282_CR78","doi-asserted-by":"crossref","first-page":"E2518","DOI":"10.1073\/pnas.1306832110","volume":"110","author":"M Talantova","year":"2013","unstructured":"Talantova M, Sanz-Blasco S, Zhang X, et al. Abeta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci USA. 2013;110:E2518\u201327.","journal-title":"Proc Natl Acad Sci USA"},{"key":"282_CR79","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40261-015-0296-4","volume":"35","author":"R Boinpally","year":"2015","unstructured":"Boinpally R, Chen L, Zukin SR, et al. A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer\u2019s disease: two phase I studies in healthy volunteers. Clin Drug Investig. 2015;35:427\u201335.","journal-title":"Clin Drug Investig"},{"key":"282_CR80","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000430808","volume":"40","author":"N Zhang","year":"2015","unstructured":"Zhang N, Wei C, Du H, et al. The effect of memantine on cognitive function and behavioral and psychological symptoms in mild-to-moderate Alzheimer\u2019s disease patients. Dement Geriatr Cogn Disord. 2015;40:85\u201393.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"282_CR81","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2017.20373","volume":"319","author":"A Atri","year":"2018","unstructured":"Atri A, Frolich L, Ballard C, et al. Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: three randomized clinical trials. JAMA. 2018;319:130\u201342.","journal-title":"JAMA"},{"key":"282_CR82","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12883-017-0800-y","volume":"17","author":"SY Tai","year":"2017","unstructured":"Tai SY, Chen CH, Chien CY, et al. Cilostazol as an add-on therapy for patients with Alzheimer\u2019s disease in Taiwan: a case control study. BMC Neurol. 2017;17:40.","journal-title":"BMC Neurol"},{"key":"282_CR83","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3233\/JAD-150978","volume":"51","author":"H Florian","year":"2016","unstructured":"Florian H, Meier A, Gauthier S, et al. Efficacy and safety of ABT-126 in subjects with mild-to-moderate Alzheimer\u2019s disease on stable doses of acetylcholinesterase inhibitors: a randomized, double-blind placebo-controlled study. J Alzheimers Dis. 2016;51:1237\u201347.","journal-title":"J Alzheimers Dis"},{"key":"282_CR84","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/WAD.0000000000000093","volume":"29","author":"RA Lenz","year":"2015","unstructured":"Lenz RA, Pritchett YL, Berry SM, et al. Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease. Alzheimer Dis Assoc Disord. 2015;29:192\u20139.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"282_CR85","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3233\/JAD-150414","volume":"48","author":"S Gauthier","year":"2015","unstructured":"Gauthier S, Rountree S, Finn B, et al. Effects of the acetylcholine release agent ST101 with donepezil in Alzheimer\u2019s disease: a randomized phase 2 study. J Alzheimers Dis. 2015;48:473\u201381.","journal-title":"J Alzheimers Dis"},{"key":"282_CR86","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JAD-141959","volume":"45","author":"S Lovestone","year":"2015","unstructured":"Lovestone S, Boada M, Dubois B, et al. A phase II trial of tideglusib in Alzheimer\u2019s disease. J Alzheimers Dis. 2015;45:75\u201388.","journal-title":"J Alzheimers Dis"},{"key":"282_CR87","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3233\/JAD-170161","volume":"58","author":"TJ Nelson","year":"2017","unstructured":"Nelson TJ, Sun MK, Lim C, et al. Bryostatin effects on cognitive function and PKCvarepsilon in Alzheimer\u2019s disease phase IIa and expanded access trials. J Alzheimers Dis. 2017;58:521\u201335.","journal-title":"J Alzheimers Dis"},{"key":"282_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2569","volume":"32","author":"K Boland","year":"2017","unstructured":"Boland K, Moschetti V, Dansirikul C, et al. A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers. Hum Psychopharmacol Clin Exp. 2017;32:e2569. https:\/\/doi.org\/10.1002\/hup.2569.","journal-title":"Hum Psychopharmacol Clin Exp."},{"key":"282_CR89","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/bcp.13060","volume":"82","author":"V Moschetti","year":"2016","unstructured":"Moschetti V, Boland K, Feifel U, et al. First-in-human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males. Br J Clin Pharmacol. 2016;82:1315\u201324.","journal-title":"Br J Clin Pharmacol"},{"key":"282_CR90","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/bph.13699","volume":"174","author":"SP Webster","year":"2017","unstructured":"Webster SP, McBride A, Binnie M, et al. Selection and early clinical evaluation of the brain-penetrant 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor UE2343 (Xanamem). Br J Pharmacol. 2017;174:396\u2013408.","journal-title":"Br J Pharmacol"},{"key":"282_CR91","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00259-016-3510-6","volume":"44","author":"S Sturm","year":"2017","unstructured":"Sturm S, Forsberg A, Nave S, et al. Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer\u2019s disease and elderly controls after oral administration of sembragiline. Eur J Nucl Med Mol Imaging. 2017;44:382\u201391.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"282_CR92","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/brain\/aww359","volume":"140","author":"S Reeves","year":"2017","unstructured":"Reeves S, McLachlan E, Bertrand J, et al. Therapeutic window of dopamine D2\/3 receptor occupancy to treat psychosis in Alzheimer\u2019s disease. Brain. 2017;140:1117\u201327.","journal-title":"Brain"},{"key":"282_CR93","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3233\/JAD-160758","volume":"57","author":"V Bloniecki","year":"2017","unstructured":"Bloniecki V, Aarsland D, Blennow K, et al. Effects of risperidone and galantamine treatment on Alzheimer\u2019s disease biomarker levels in cerebrospinal fluid. J Alzheimers Dis. 2017;57:387\u201393.","journal-title":"J Alzheimers Dis"},{"key":"282_CR94","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.4088\/JCP.14m09740","volume":"77","author":"YM Lee","year":"2016","unstructured":"Lee YM, Park JM, Lee BD, et al. Gray matter volumes and treatment response of psychotic symptoms to risperidone in antipsychotic-naive Alzheimer\u2019s disease patients. J Clin Psychiatry. 2016;77:e8-13.","journal-title":"J Clin Psychiatry"},{"key":"282_CR95","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3109\/07420528.2015.1077855","volume":"32","author":"TC Grippe","year":"2015","unstructured":"Grippe TC, Goncalves BS, Louzada LL, et al. Circadian rhythm in Alzheimer disease after trazodone use. Chronobiol Int. 2015;32:1311\u20134.","journal-title":"Chronobiol Int"},{"key":"282_CR96","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000435889","volume":"96","author":"Y Yin","year":"2015","unstructured":"Yin Y, Liu Y, Zhuang J, et al. Low-dose atypical antipsychotic risperidone improves the 5-year outcome in Alzheimer\u2019s disease patients with sleep disturbances. Pharmacology. 2015;96:155\u201362.","journal-title":"Pharmacology"},{"key":"282_CR97","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/psyg.12085","volume":"15","author":"H Suzuki","year":"2015","unstructured":"Suzuki H, Gen K. Clinical efficacy of lamotrigine and changes in the dosages of concomitantly used psychotropic drugs in Alzheimer\u2019s disease with behavioural and psychological symptoms of dementia: a preliminary open-label trial. Psychogeriatrics. 2015;15:32\u20137.","journal-title":"Psychogeriatrics"},{"key":"282_CR98","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jagp.2019.05.002","volume":"27","author":"N Herrmann","year":"2019","unstructured":"Herrmann N, Ruthirakuhan M, Gallagher D, et al. Randomized placebo-controlled trial of nabilone for agitation in Alzheimer\u2019s disease. Am J Geriatr Psychiatry. 2019;27:1161\u201373.","journal-title":"Am J Geriatr Psychiatry"},{"key":"282_CR99","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3233\/JAD-160225","volume":"55","author":"H An","year":"2017","unstructured":"An H, Choi B, Park KW, et al. The effect of escitalopram on mood and cognition in depressive Alzheimer\u2019s disease subjects. J Alzheimers Dis. 2017;55:727\u201335.","journal-title":"J Alzheimers Dis"},{"key":"282_CR100","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/gps.4384","volume":"31","author":"YM Choe","year":"2016","unstructured":"Choe YM, Kim KW, Jhoo JH, et al. Multicenter, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression-delaying effects in Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2016;31:731\u20139.","journal-title":"Int J Geriatr Psychiatry"},{"key":"282_CR101","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.jagp.2015.05.006","volume":"23","author":"D Weintraub","year":"2015","unstructured":"Weintraub D, Drye LT, Porsteinsson AP, et al. Time to response to citalopram treatment for agitation in Alzheimer disease. Am J Geriatr Psychiatry. 2015;23:1127\u201333.","journal-title":"Am J Geriatr Psychiatry"},{"key":"282_CR102","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/appi.ajp.2016.15020248","volume":"173","author":"AK Leonpacher","year":"2016","unstructured":"Leonpacher AK, Peters ME, Drye LT, et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer\u2019s dementia: evidence from the CitAD study. Am J Psychiatry. 2016;173:473\u201380.","journal-title":"Am J Psychiatry"},{"key":"282_CR103","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1176\/appi.ajp.2015.15050648","volume":"173","author":"LS Schneider","year":"2016","unstructured":"Schneider LS, Frangakis C, Drye LT, et al. Heterogeneity of treatment response to citalopram for patients with Alzheimer\u2019s disease with aggression or agitation: the CitAD randomized clinical trial. Am J Psychiatry. 2016;173:465\u201372.","journal-title":"Am J Psychiatry"},{"key":"282_CR104","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpsychires.2015.12.005","volume":"74","author":"J Newell","year":"2016","unstructured":"Newell J, Yesavage JA, Taylor JL, et al. Sedation mediates part of Citalopram\u2019s effect on agitation in Alzheimer\u2019s disease. J Psychiatr Res. 2016;74:17\u201321.","journal-title":"J Psychiatr Res"},{"key":"282_CR105","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3233\/JAD-160675","volume":"56","author":"A Carotenuto","year":"2017","unstructured":"Carotenuto A, Rea R, Traini E, et al. The effect of the association between donepezil and choline alphoscerate on behavioral disturbances in Alzheimer\u2019s disease: interim results of the ASCOMALVA trial. J Alzheimers Dis. 2017;56:805\u201315.","journal-title":"J Alzheimers Dis"},{"key":"282_CR106","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3233\/JAD-141983","volume":"48","author":"R Rea","year":"2015","unstructured":"Rea R, Carotenuto A, Traini E, et al. Apathy treatment in alzheimer\u2019s disease: interim results of the ASCOMALVA trial. J Alzheimers Dis. 2015;48:377\u201383.","journal-title":"J Alzheimers Dis"},{"key":"282_CR107","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/ggi.12754","volume":"17","author":"SJ Yoon","year":"2017","unstructured":"Yoon SJ, Choi SH, Na HR, et al. Effects on agitation with rivastigmine patch monotherapy and combination therapy with memantine in mild to moderate Alzheimer\u2019s disease: a multicenter 24-week prospective randomized open-label study (the Korean EXelon Patch and combination with mEmantine Comparative Trial study). Geriatr Gerontol Int. 2017;17:494\u20139.","journal-title":"Geriatr Gerontol Int"},{"key":"282_CR108","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/gps.1949","volume":"23","author":"S Gauthier","year":"2008","unstructured":"Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer\u2019s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008;23:537\u201345.","journal-title":"Int J Geriatr Psychiatry"},{"key":"282_CR109","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1017\/neu.2015.61","volume":"28","author":"I Ishikawa","year":"2016","unstructured":"Ishikawa I, Shinno H, Ando N, et al. The effect of memantine on sleep architecture and psychiatric symptoms in patients with Alzheimer\u2019s disease. Acta Neuropsychiatr. 2016;28:157\u201364.","journal-title":"Acta Neuropsychiatr"},{"key":"282_CR110","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jamda.2014.11.002","volume":"16","author":"C Ballard","year":"2015","unstructured":"Ballard C, Thomas A, Gerry S, et al. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer\u2019s disease (MAIN-AD). J Am Med Dir Assoc. 2015;16:316\u201322.","journal-title":"J Am Med Dir Assoc"},{"key":"282_CR111","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jama.2015.10214","volume":"314","author":"JL Cummings","year":"2015","unstructured":"Cummings JL, Lyketsos CG, Peskind ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314:1242\u201354.","journal-title":"JAMA"},{"key":"282_CR112","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/mds.25674","volume":"28","author":"M Amboni","year":"2013","unstructured":"Amboni M, Barone P, Hausdorff JM. Cognitive contributions to gait and falls: evidence and implications. Mov Disord. 2013;28:1520\u201333.","journal-title":"Mov Disord"},{"key":"282_CR113","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3233\/JAD-140759","volume":"43","author":"M Montero-Odasso","year":"2015","unstructured":"Montero-Odasso M, Muir-Hunter SW, Oteng-Amoako A, et al. Donepezil improves gait performance in older adults with mild Alzheimer\u2019s disease: a phase II clinical trial. J Alzheimers Dis. 2015;43:193\u20139.","journal-title":"J Alzheimers Dis"},{"key":"282_CR114","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s40266-016-0391-0","volume":"33","author":"O Beauchet","year":"2016","unstructured":"Beauchet O, Barden J, Liu-Ambrose T, et al. Anti-dementia drugs, gait performance and mental imagery of gait: a non-randomized open-label trial. Drugs Aging. 2016;33:665\u201373.","journal-title":"Drugs Aging"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-021-00282-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-021-00282-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-021-00282-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T13:33:23Z","timestamp":1636119203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-021-00282-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["282"],"URL":"https:\/\/doi.org\/10.1007\/s40120-021-00282-z","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"assertion":[{"value":"7 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}